Cogent Biosciences, Inc. Restructuring Charges
Cogent Biosciences, Inc. (COGT) reported Restructuring Charges of $4.17 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2021-03-16
- Cogent Biosciences, Inc. restructuring charges for the quarter ending 2020-12-31 was $1.49M.
- Cogent Biosciences, Inc. restructuring charges for the quarter ending 2020-09-30 was $833.00K.
- Cogent Biosciences, Inc. restructuring charges for the quarter ending 2020-06-30 was $143.00K.
- Cogent Biosciences, Inc. restructuring charges for the quarter ending 2020-03-31 was $1.70M.
- Cogent Biosciences, Inc. restructuring charges for fiscal 2020 was $4.17M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.32M derived: sum of 2 quarters · filed 2021-03-16 | $2.46M derived: sum of 3 quarters · filed 2021-03-16 | $4.17M 10-K · filed 2021-03-16 |
| 2020-09-30 | $833.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $976.00K derived: sum of 2 quarters · filed 2020-11-09 | $2.68M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $1.84M 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $1.70M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |